NCT01723111View on ClinicalTrials.gov

Impact of Dialysis Modality on Hepcidin and Iron Metabolism

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

August 31, 2016

Conditions
End-stage Renal Disease
Trial Locations (4)

700-721

Daegu Fatima Hospital, Daegu

Dongsan Medical Center, Daegu

Kyungpook National University Hospital, Daegu

705-717

Yeungnam University College of Medicine, Daegu

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Fresenius Medical Care North America

INDUSTRY

lead

Kyungpook National University Hospital

OTHER

NCT01723111 - Impact of Dialysis Modality on Hepcidin and Iron Metabolism | Biotech Hunter | Biotech Hunter